FRANKLIN LAKES, N.J., Nov. 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Paddy O’Brien to worldwide president, Peripheral Intervention, effective October 24.
In his new role, O’Brien will have responsibility for driving global strategic, operational and commercial performance across the Peripheral Intervention portfolio, which includes focused areas of oncology, peripheral arterial disease and end-stage kidney disease.
“Paddy brings unique capabilities to the leadership role in Peripheral Intervention, with a proven history of unparalleled product innovation, attention to product quality, customer focus and delivering consistent and meaningful business results,” said Simon Campion, executive vice president and president of the BD Interventional Segment. “In addition to his business impact, Paddy’s knowledge of the healthcare industry, strategic vision and embracing of diverse perspectives make him an exceptional choice for this role.”
O’Brien began his career at BD over 20 years ago, holding positions of increasing responsibility, including vice president of marketing and vice president of sales for peripheral intervention. Most recently, he served as the vice president and general manager for the global platform focused on solutions for peripheral arterial disease and end-stage kidney disease.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
Contacts:
Jessica Offerjost
BD Public Relations
201.847.5297
Jessica.Offerjost@bd.com
Kristen M. Stewart, CFA
BD Investor Relations
201.847.5378
kristen.stewart@bd.com